Dow Jones

40 954,48

1,85%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NYSE
Teva Pharmaceutical Industries Ltd (TEVA)
Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NYSE:TEVA

<< Précédent 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
03/08/2023	13h33	IH Market News	Thursday’s Wall Street Highlights: Anheuser-Busch InBev, Apple, Hasbro, Sunrun and more	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
02/08/2023	22h16	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
02/08/2023	22h06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
02/08/2023	13h00	Business Wire	Teva Reports Second Quarter 2023 Financial Results	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
27/07/2023	14h00	Business Wire	Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
24/07/2023	10h00	Business Wire	Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
05/07/2023	22h30	Business Wire	Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
01/07/2023	11h37	Business Wire	Tevas dritte Zwischenanalyse der PEARL-Real-World-Studie zu AJOVY® (Fremanezumab) zeigt anhaltende langfristige Wirksamkeit bei der Verringerung von Häufigkeit, Dauer und Schwere der Anfälle bei Patienten mit chronischer und episodischer Migräne	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
01/07/2023	00h13	Business Wire	Les 3 de Tevard Analyse intermédiaire de l'étude PEARL en situation réelle sur AJOVY® (fremanezumab) révèle une efficacité soutenue à long terme dans la réduction de la fréquence, de la durée et de la sévérité des crises chez les patients att	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
30/06/2023	18h30	Business Wire	Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
20/06/2023	13h40	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
15/06/2023	22h02	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
15/06/2023	14h00	Business Wire	Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
13/06/2023	00h40	Dow Jones News	Correction to Teva Pharmaceutical Headline, Article	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
12/06/2023	22h44	Dow Jones News	Teva Pharmaceutical Agrees to Pay $1.41 Billion to Settle Kentucky Price-Fixing Claims	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
12/06/2023	22h00	Business Wire	Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
12/06/2023	13h00	Business Wire	Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
09/06/2023	18h33	Edgar (US Regulatory)	Schedule 13g (sc 13g/a)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
09/06/2023	16h39	Dow Jones News	NY AG Lands Final Approval for $17.3 Billion Opioid Settlement	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
08/06/2023	15h27	Dow Jones News	Teva Pharma Reaches Opioid Settlement With Nevada, the Final State to Resolve Claims	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
08/06/2023	14h30	Business Wire	Teva Concludes Nationwide Opioids Settlement Agreement	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
06/06/2023	14h00	Business Wire	Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
02/06/2023	22h30	Business Wire	Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
24/05/2023	22h29	Edgar (US Regulatory)	Specialized Disclosure Report (sd)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
24/05/2023	22h16	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
20/05/2023	17h00	Business Wire	Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
18/05/2023	14h30	Business Wire	Teva Launches New “Pivot to Growth” Strategy	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
15/05/2023	14h00	Business Wire	AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
10/05/2023	22h05	Edgar (US Regulatory)	Quarterly Report (10-q)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
10/05/2023	13h00	Business Wire	Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook	NYSE:TEVA	Teva Pharmaceutical Industries Ltd